// App-Quantinova.ai

1354 ⋆ : Time course of treatment‐emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment

Researchers

Presenter

  • Philippe Merle

Principal Investigators

  • Yi-Hsiang Huang

  • Gyorgy Bodoky

  • Marc Pracht

  • Osamu Yokosuka

  • Olivier Rosmorduc

  • Valeriy Breder

  • Ren Gerolami

  • Gianluca Masi

  • Paul J. Ross

  • Shukui Qin

  • Tianqiang Song

  • JeanPierre Bronowicki

  • Isabelle Ollivier-Hourmand

  • Masatoshi Kudo

  • Sarah Schlief

  • Sabine Fiala-Buskies

  • Gerold Meinhardt

Medical Centers

  • Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France

  • Department of Medical and Surgical Sciences, University of Bologna – S.Orsola-Malpighi Hospital, Bologna, Italy

  • Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

  • St. Laszlo Teaching Hospital, Budapest, Hungary

  • Service d'Oncologie Medicale, Central Eugene Marquis, Rennes, France

  • Department of Gastroenterology and Nephrology, Chiba University Hospital, Chiba, Japan

  • Hopital de la Pitie-Salpétrière, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie, Sorbonne Universités, Paris, France

  • Russian Cancer Research Centre n.a.N.Blokhin, Moscow, Russia

  • CHU Timone, Université de la Méditerranée, Marseille, France

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • INSERM 954, CHU de Nancy, Universite de Lorraine, Nancy, France

  • Service d'Hepatogastroenterologie, CHU, Caen, France

  • Niigata University School of Medicine, Niigata, Japan

  • Bayer, Berlin, Germany

  • Bayer Pharma AG, Berlin, Germany

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain

Locations

  • France

  • Italy

  • Taiwan

  • Hungary

  • Japan

  • Russia

  • United Kingdom

  • China

  • Germany

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Regorafenib

  • Sorafenib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved